CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Palonosetron hydrochloride

Last Updated: October 5, 2012
Result type: Reports
Project Number: SR0293-000
Product Line: Reimbursement Review

Generic Name: Palonosetron hydrochloride

Brand Name: Aloxi (injection)

Manufacturer: Eisai Ltd.

Therapeutic Area: Chemotherapy-induced nausea and vomiting

Indications: Nausea and vomiting (chemotherapy induced) prevention

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 15, 2013

Recommendation Type: Do not list at the submitted price